NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Key Financial Metrics1:  Three Months EndedDecember 31,   Twelve Months EndedDecember 31,(in millions USD)   2025       2024     % Change     2025       2024     % ChangeRevenue $ 352.2     $ 234.6     50 %   $ 1,300.5     $ 889.9     46 %Gross profit   120.4       56.1     115 %     429.1       192.1     123 %Net loss   (428.2 )     (0.2 )   NM     (517.1 )     (0.7 )   NMNet cash provided by operating activities   7.3       42.7     (83 )%     7.6       68.6     (89 )%                       Non-GAAP Financial Data*                      Ex-TAC gross profit   151.8       68.3     122 %     529.7       236.1     124 %Adjusted...

Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarter Recorded second consecutive quarter of profitabilityMORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update. Dr....

Delivered 4% Y/Y Net Sales Growth Drove 34% Y/Y Bookings Growth in Fine JewelryProvides Q1 and Full Year Guidance 2026 SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced financial results for the three and twelve months ended December 31, 2025. Fourth Quarter and Fiscal Year 2025 Highlights (quarterly and annual periods ended December 31, 2025):Delivered Net Sales of $124.4 million and $437.5 million in the fourth quarter and fiscal year, respectively.Largest quarter ever of Net Sales Total orders grew year-over-year 7% in Q4 and 13% in 2025 Repeat orders grew year-over-year 15% in Q4 and 13% in 2025 Average Selling Price (ASP) grew year-over-year across the assortment...

NEW YORK, NY, March 05, 2026 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: “We ended 2025 on a high note with fourth quarter sales growth of 4.3%. In 2025, we delivered on our Bonds & Beyond transformation priorities, driving renewed brand momentum and building a consistent innovation pipeline while strengthening execution and sharpening strategic focus. As we enter 2026, we do so with a clear path forward and a more balanced, sustainable approach to investment and growth.” For the fourth quarter of 2025 compared to the fourth quarter of 2024:Net sales increased 4.3% to $105.1 million;By...

Q4 total sales grew 11%, and comparable store sales increased 4%  Q4 net income was $310 million, and diluted EPS was $4.84 FY25 total sales grew 9%, and comparable store sales increased 2% FY25 net income was $610 million, and diluted EPS was $9.51 Excluding expenses associated with bankruptcy acquired leases:Q4 Adjusted EBIT margin increased 100 basis points versus Q4 of FY24 Q4 Adjusted EPS increased 21% to $4.99, versus guidance of $4.50 to $4.70 FY25 Adjusted EBIT margin of 8.0%, an increase of 80 basis points versus FY24 FY25 Adjusted EPS of $10.17, an increase of 22% versus FY24BURLINGTON, N.J., March 05, 2026 (GLOBE NEWSWIRE) — Burlington Stores, Inc. (NYSE: BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices,...

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program to first topline Phase 3 results in...

Municipality Finance PlcStock exchange release5 March 2026 at 1:00 pm (EET) Municipality Finance Group’s Annual Report for 2025 published Municipality Finance Group’s Annual Report and Corporate Governance Statement for the year 2025 have been published in English and Finnish. MuniFin Group’s Annual Report fulfils the reporting requirements of European Single Electronic Format (ESEF). In accordance with these requirements, Report of the Board of Directors and the Consolidated Financial Statements are published not only in the Annual Report file but additionally in a separate zip file in which Report of the Board and the Financial Statements are marked up with XBRL tags. These ESEF Financial Statements have been subject to an independent auditor’s assurance. MuniFin Group has also published Pillar 3 Disclosure document in accordance with...

— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — — Rapidly progressing groundbreaking ATTC technology, a source of novel drug candidates with broad therapeutic potential — — Pursuing potential opportunities for partnering ATTC candidates with multinational pharmaceutical companies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J. , March 05, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the year ended December 31, 2025 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts at 8:00 a.m. EST / 1:00 p.m. GMT / 9:00 p.m. HKT in English on Thursday,...

Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 –AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights. “SL-325 is now the first DR3 blocking antibody to generate human clinical data, and we are very pleased with the progress we have made in our...

SHANGHAI, March 05, 2026 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights:Average daily active users (DAUs) were 113.0 million, an increase of 10% year over year. Average daily time spent per active user were 107 minutes, an increase of 8% year over year. Total net revenues were RMB8.32 billion (US$1,189.9 million), an increase of 8% year over year. Advertising revenues, a key driver of total net revenues, were RMB3.04 billion (US$435.0 million), an increase of 27% year over year. Gross profit was RMB3.08 billion (US$440.6 million), an increase of 11% year over year....